Landmarks: examining the foundation for GP IIb/IIIa inhibitors in PCI.
D015906:Angioplasty, Balloon, Coronary / Q000379:methods*; D015415:Biomarkers / Q000032:analysis; D002097:C-Reactive Protein / Q000032:analysis*; D003131:Combined Modality Therapy; D003324:Coronary Artery Disease / Q000175:diagnosis* / Q000628:therapy*; D023921:Coronary Stenosis / Q000175:diagnosis* / Q000628:therapy*; D005260:Female; D006801:Humans; D008297:Male; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors*; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment; D012720:Severity of Illness Index; D015607:Stents; D016896:Treatment Outcome
D015415:Biomarkers; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D002097:C-Reactive Protein